Skip to main content
. 2017 Jan 18;17:11. doi: 10.1186/s12883-016-0789-7

Table 1.

Patient demographics and relevant baseline characteristics

Fingolimod 0.5 mg (N = 3951)
Age groups in years, n (%)
 18–30 880 (22.3)
  > 30–40 1222 (30.9)
  > 40–55 1622 (41.1)
  > 55–65 208 (5.3)
  > 65 18 (0.5)
Sex
 Female, n (%) 2779 (70.3)
Duration of MS since first symptoms in years, mean ± SD 10.0 ± 7.6
Number of relapses in previous year, mean ± SD 1.6 ± 1.2
EDSS, mean ± SD 2.8 ± 1.6
DMT treatment within the last 6 months, n (%)
 No 827 (20.9)
 Yes 3124 (79.1)